These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 23079391)

  • 21. Management of reflux-related symptoms.
    Dutta U; Moayyedi P
    Best Pract Res Clin Gastroenterol; 2013 Jun; 27(3):387-400. PubMed ID: 23998977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and characteristics of acid gastro-oesophageal reflux disease in Jackhammer oesophagus.
    Mallet AL; Ropert A; Bouguen G; Siproudhis L; Boutroux D; Bretagne JF; Brochard C
    Dig Liver Dis; 2016 Oct; 48(10):1136-41. PubMed ID: 27453169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Gastro-oesophageal reflux disease-update 2021].
    Labenz J; Borkenstein DP; Müller M; Labenz G
    Internist (Berl); 2020 Dec; 61(12):1249-1263. PubMed ID: 33112963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined multichannel intraluminal impedance and pH monitoring is helpful in managing children with suspected gastro-oesophageal reflux disease.
    Rossi P; Isoldi S; Mallardo S; Papoff P; Rossetti D; Dilillo A; Oliva S
    Dig Liver Dis; 2018 Sep; 50(9):910-915. PubMed ID: 29724467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reflux monitoring: pH-metry, Bilitec and oesophageal impedance measurements.
    Pohl D; Tutuian R
    Best Pract Res Clin Gastroenterol; 2009; 23(3):299-311. PubMed ID: 19505660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refractory gastro-oesophageal reflux disease: diagnosis and management.
    Liu JJ; Saltzman JR
    Drugs; 2009 Oct; 69(14):1935-44. PubMed ID: 19747009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors.
    Zerbib F; Duriez A; Roman S; Capdepont M; Mion F
    Gut; 2008 Feb; 57(2):156-60. PubMed ID: 17951358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.
    Shaheen NJ; Denison H; Björck K; Karlsson M; Silberg DG
    Gut; 2013 Sep; 62(9):1248-55. PubMed ID: 22730470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
    Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
    Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease.
    Pace F; Pallotta S; Bianchi Porro G
    Dig Liver Dis; 2002 Dec; 34(12):870-7. PubMed ID: 12643297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both?
    Tack J; Koek G; Demedts I; Sifrim D; Janssens J
    Am J Gastroenterol; 2004 Jun; 99(6):981-8. PubMed ID: 15180713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refractory gastroesophageal reflux disease.
    Moraes-Filho JP
    Arq Gastroenterol; 2012 Dec; 49(4):296-301. PubMed ID: 23329226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease--Bilitec, intraluminal impedance and Bravo capsule pH monitoring.
    Hirano I
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():12-24. PubMed ID: 16483266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
    Egan LJ; Myhre GM; Mays DC; Dierkhising RA; Kammer PP; Murray JA
    Aliment Pharmacol Ther; 2003 Jun; 17(12):1521-8. PubMed ID: 12823155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastroesophageal reflux disease (GERD) in children.
    Poddar U
    Paediatr Int Child Health; 2019 Feb; 39(1):7-12. PubMed ID: 30080479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
    Calabrese C; Liguori G; Gabusi V; Gionchetti P; Rizzello F; Straforini G; Brugnera R; Di Febo G
    Aliment Pharmacol Ther; 2008 Jul; 28(2):250-5. PubMed ID: 18485128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
    Gardner JD; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1381-6. PubMed ID: 15606401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton pump inhibitor failure in gastro-oesophageal reflux disease: a perspective aided by the Gartner hype cycle.
    Heading RC
    Clin Med (Lond); 2017 Apr; 17(2):132-136. PubMed ID: 28365622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease.
    Ofman JJ; Dorn GH; Fennerty MB; Fass R
    Aliment Pharmacol Ther; 2002 Feb; 16(2):261-73. PubMed ID: 11860409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.